Long-Term Safety of Dupilumab in Adults with Moderate to Sev

The results from this 5-year, open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Related Keywords

Nevada , United States , Las Vegas , , Clinical Dermatology Conference , Monstar Studios , Eczema Area , Severity Index , Global Assessment , Peak Pruritus Numerical Rating Scale , Atopic Dermatitis , Dupilumab , Fall Clinical Dermatology ,